Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

If you have access to Ample a poster there makes a few valid points (wowbagger). Am still in from last year (did not take profits) and will hold as believe this company has lots of potential, looking forward to brokers note whenever that may appear. Good luck to all holders.

news on BPRG SITE-don't know how to get it on here.

ep

Here it is:-

03 June 2004
Update on FMC BioPolymer Global Licensing Agreement
In February 2004, BioProgress plc (BioProgress) announced an agreement with FMC BioPolymer (FMC), a business unit of FMC Corporation (NYSE:FMC) whereby FMC acquired an exclusive worldwide licence for the BioProgress NROBE dosage form, process, equipment and enabling technology. FMC has subsequently assumed full responsibility for the commercialisation of NROBE and has a team of technical and commercial staff focused on NROBE development, primarily at its Princeton, New Jersey and Brussels, Belgium laboratories.

The licensing agreement runs to 2023 and FMC has provided contractual assurances that a minimum number of NROBE machines will be purchased from BioProgress within the first six years following commercialisation. It is the continued expectation of BioProgress that the contracts are likely to generate a minimum of US$160 million of revenue to BioProgress over the first six years following commercialisation, including machine sales, film manufacturing contract sales and royalties payable to BioProgress on the revenues generated by FMC from sales of film, whether produced or developed by BioProgress or by FMC, for use with the NROBE dosage form.

As part of the drive towards commercialisation, FMC has now executed agreements with subsidiaries of Grupo Farmasierra (Farmasierra), whereby Farmasierra will provide FMC with technology development and manufacturing services relating to the commercialisation of NROBE. Under these agreements, Farmasierra will work closely with FMC to support the development of NROBE technology for pharmaceutical applications. Farmasierra will be FMCs exclusive contract manufacturing partner for NROBE in Europe during the initial commercialization phase. By establishing these agreements, FMC expects to accelerate its development plans for NROBE and to be able to offer contract manufacturing services at the earliest possible stage.

Graham Hind, Chief Executive of BioProgress, said: These agreements between FMC BioPolymer and Farmasierra bring together a global pharmaceutical supplier and a company with a reputation for superior quality contract manufacturing services. I also believe they validate our confidence in NROBE and its potential for capturing a significant share of the sizeable market for capsules and tablets over the long-term. Finally, it means that the commercialisation of NROBE is likely to be accelerated, which has positive implications for the start of revenue flows for BioProgress.

JOEHARGAN1-THANKS

Exclusive licensing option agreement with Wyeth for XGEL(R) SWALLOW liquid fill capsule technology


Looking good

http://www.uk-wire.com/cgi-bin/articles/200406070700044490z.html

BioProgress PLC
07 June 2004


Press Release 7 June 2004


BioProgress plc

('BioProgress' or 'the Company')


Exclusive licensing option agreement with Wyeth
for XGEL(R) SWALLOW liquid fill capsule technology


BioProgress plc, a provider of innovative delivery mechanisms for the
pharmaceutical oral dosage markets, announces today it has executed an exclusive
option agreement with Wyeth to complete due diligence and enter into
negotiations to license its XGEL(R) SWALLOW liquid fill capsule technology for
certain specified product fields.

The option agreement provides for an upfront payment of a six figure sum on
execution providing Wyeth with an exclusive opportunity to evaluate the
technology and negotiate terms of a technology licensing agreement, machine
supply agreement and the film supply agreement within the fields. Francis
Sullivan, spokesperson for Wyeth Consumer Healthcare, said: 'We believe
BioProgress has developed some interesting technology. We are entering into
this agreement to secure an exclusive position to enable a full detailed
evaluation of the opportunity.'

It is intended that BioProgress through Harro Hoefliger will provide liquid fill
XGEL(R) machines and BioProgress will supply film for the machines from its
newly acquired film production facility in Tampa, Florida USA, and from its UK
film production facility when that comes on-line. BioProgress will also receive
a licence fee within any exclusively licensed product field which uses the
liquid dosage form.

Graham Hind, Chief Executive Officer of BioProgress plc, said: 'This is a
significant agreement for BioProgress as it involves another of our new dosage
form technologies with a major US pharmaceutical customer.

'XGEL(R) SWALLOW liquid fill capsule technology has unique properties which
makes it a very attractive delivery platform for pharmaceutical manufacturers.
We believe this technology has the potential to be the preferred alternative to
current liquid fill systems'.

New OTC deal in the frame for BioProgress?

- 08/06/2004 - UK encapsulation specialist BioProgress has signed a license option deal for a liquid fill technology with the consumer healthcare division of US drug major Wyeth. If taken to fruition, the agreement would mark the companys second partnership in the over-the-counter (OTC) drug sector.

Wyeth is evaluating BioProgress XGEL SWALLOW liquid fill capsule technology for certain specified product fields. The SWALLOW system makes use of a single, compact machine is claimed to improve on the lengthy, multi-step manufacturing process required for gelatin soft capsules. Wyeth is thought to be the first commercial partner for this technology.
In March, BioProgress signed an agreement for its TABWRAP tablet coating technology with an unnamed company that will use it for OTC applications. Both SWALLOW and TABWRAP are based on BioProgress' animal-free cellulose film technology.

The option agreement provides for an upfront payment of an unspecified six-figure sum on execution. Wyeth will evaluate the technology and, if its deliberations are positive, can negotiate terms of a technology license and machine/film supply agreement.

It is intended that BioProgress - through its machinery partner Harro Hoefliger - will provide liquid fill XGEL machines and BioProgress will supply film for the machines from its newly acquired film production facility in Florida, US, and from its UK film production facility when that comes on-line.

Graham Hind, BioProgress chief executive, said that the company is positioning SWALLOW as a preferred alternative to current liquid fill systems, helped by the fact that its use of a single, compact machine is an improvement over the lengthy, multistep manufacturing process required for gelatin.

With most of the capital-intensive infrastructure eliminated, SWALLOW makes it easier for companies to adopt in-house production. And as capacity requirements increase, more self-contained systems can simply be added, claims the UK company.

SWALLOW capsules can be produced in a variety of shapes, sizes, colours and thickness, and can be modified to meet specific customer and product requirements for dissolution
http://www.inpharma.com/news/news-NG.asp?id=52654

BioProgress plc

('BioProgress' or 'the Company')

NASDAQ listing


BioProgress plc, a provider of innovative delivery mechanisms for the
pharmaceutical oral dosage markets, announces that the board of directors of the
Company has decided to apply to list American Depository Receipts (or ADRs)
representing Ordinary Shares of the Company on the NASDAQ National Market.

The dual NASDAQ listing will create a more efficient trading platform for the
significant number of US-based Shareholders that BioProgress already has, as
well as any new US shareholders. Since the Company is already required to file
reports with the US Securities and Exchange Commission, the additional costs and
regulatory hurdles involved in a dual listing on the NASDAQ National Market will
be relatively small.

Since BioProgress Technology International Inc. delisted from the NASD OTC
Bulletin Board in May 2003, the Company now has a significant part of its
business in the USA. This includes important agreements signed with US-based
pharmaceutical companies as well as the acquisition of certain assets of the
Aquafilm business in Florida.

BioProgress is currently looking to appoint US advisers to assist in this
process and will provide further information at an appropriate stage.


Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. This announcement contains certain 'forward-looking
statements' within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking statements.
The forward-looking statements in this release include statements addressing
future financial and operating results and the timing and benefits of the
reorganisation. Detailed information about factors pertinent to the business of
the company that could cause actual results to differ is set forth in the
Company's filings with the Securities and Exchange Commission. The Company is
under no obligation to (and expressly disclaim any such obligation to) update or
alter its forward-looking statements whether as a result of new information,
future events or otherwise.

- Ends -


For further information:
BioProgress plc
Graham Hind, Chief Executive Tel: +44 (0) 1354 655 674
grahamhind@bioprogress.com www.bioprogress.com

What's going on ?

God knows you tell me (us), brokers note required urgently...

Anyone know why the market has turned against this one lately? Is the listing likely to go USA only do you think?

turned against this one lately?

Its gone down from one pound and 60 pence!!!!!!!!!!!!!!!!!!!! and over some time too now.

Does anyone have a clue why this share is garbage now as its lost more than half of its recent high.

Are we going down towards 40p??

Expect a retract back to 1 before the week is out. Good news on the way. Hold tight.

Brokers note? :))

Strange! A post of mine in April mentioned a brokers note on this thread, is it the same one? Holding tight......to my money...

One of the most bearish charts around IMO.

Any news will have to be exceptional to get this back to a quid any time soon. Never say never, but...................

Just had RNS about shares, can't determine if sold or bought but indications that the founder of company has dumped 67% of holdings? If so what does the future hold, I hold shares at present...

He has sold 560,000 still has 3,437,093

Ok not so bad then he's entitled to get some cash, lol.

He's a bit slow getting rid of them if that's right....

.......unless he knows something no-one else does.

:-0

Urmmmm. Where did he B Muncaster, get the cash to buy shares in BPRG? Apparently they keep saying the directors put their houses in hock and used their credit cards to keep the company 'running' a while back.

10m shares had to be paid for from somewhere?

As has been said the sale of 560,000 shares doesn't look to be what most shareholders will appreciate, especially as it take him below the 3% threshold, he can if he wishes, sell without a declaration from now on I believe! I'm thankful I don't hold them!